Papilocare

Papilocare
Product Description

Gel for the prevention and adjuvant treatment of HPV-induced lesions:

· Medical Device Class IIa. Patented Vaginal Gel.

· Innovative & Unique (1st Treatment for HPV-dependent cervical low grade lesions)

· Target Patients: HPV+ and HPV+ with lesions (ASCUS or LSIL) 

· Indicated as a secondary prevention and treatment.

· Encapsulating system: Niosomes & Phytomsomes

· Effect on 3 modifiable factors. Unique combination for a synergistic action (1+2: Allows to modify 3)

        Reepithelization of the vaginal transformation zone

        Rebalance the vaginal microbiota

        Counteracts the non-inflammatory microenvironment

· Primary end-point: 88% HR HPV+ vs 56% CG at 6 months in clearance of cervical lesions.

· Secondary end-point: 63% HR HPV+ vs 40% CG at 6 months in HPV clearance.

· Significant reduction of Stress and high level of adherence

· Journal of Lower Genital Tract Disease: March 2021 Study Paloma Publication (Phase IIb) 



Visit our Website:
https://www.papilocare.com/

Procare Health

  • ES
  • 2018
    On CPHI since
  • 2
    Certificates
  • 50 - 99
    Employees
Company types
Manufacturer/Innovator
Specifications

Procare Health

  • ES
  • 2018
    On CPHI since
  • 2
    Certificates
  • 50 - 99
    Employees
Company types
Manufacturer/Innovator

More Products from Procare Health (2)

  • Ovosicare

    Product Ovosicare

    Contributes to the normalization of fertility and favours the development of the placenta during pregnancy:

    · Food Supplement. Patented Formulation 

    · Indicated for pre conception.

    · Target Patients: Women suffering of subfertility and late maternity...
  • Idracare

    Product Idracare

    Moisturizing vaginal gel with niosomes of hyaluronic acid in high concentration at 2% and prebiotics (increased & prolonged hydratation)

    · Medical Device Class I. Patented.

    · Target Patients: When there is a decrease in vaginal discharge – Vulvovaginal Atrophy
    ...

Procare Health resources (2)